D
Diana L. Brixner
Researcher at University of Utah
Publications - 17
Citations - 378
Diana L. Brixner is an academic researcher from University of Utah. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 254 citations.
Papers
More filters
Journal ArticleDOI
Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making
Marc L. Berger,Harold C. Sox,Richard J. Willke,Diana L. Brixner,Hans Georg Eichler,Wim G. Goettsch,David Madigan,Amr Makady,Sebastian Schneeweiss,Rosanna Tarricone,Shirley V. Wang,John B. Watkins,C. Daniel Mullins +12 more
TL;DR: Real‐world evidence (RWE) includes data from retrospective or prospective observational studies and observational registries and provides insights beyond those addressed by randomized controlled trials.
Journal ArticleDOI
Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment.
Rupesh M. Panchal,Danielle Nguyen,Priyanka Ghule,Niying Li,Theodoros V. Giannouchos,Raymond J Pan,Joseph Biskupiak,Laura Britton,Robert Nohavec,Stacey Slager,Surachat Ngorsuraches,Diana L. Brixner +11 more
TL;DR: In this article , the authors explored patients' willingness to pay (WTP) for the predetermined high-value and low-value type 2 diabetes mellitus (T2DM) treatments within a health plan.
Journal ArticleDOI
CO118 TRK Inhibitor Treatment Patterns in Patients with NTRK Fusion-Positive Solid Tumors: A Multi-Site Cohort Study at U.S. Academic Cancer Centers
CW Willis,Tatiya Au,Cassia R Griswold,MB Schabath,Jarred Thompson,Jyoti Malhotra,Gang-Ji Ko,Sreevalsa Appukkuttan,N. Warnock,S. Kong,Brian Thomas Hocum,Diana L. Brixner,David D. Stenehjem +12 more
TL;DR: In this article , the authors describe the TRKi treatment patterns in patients with NTRK-fusion positive solid tumors, and describe the treatment pattern in patients who were treated with a TRK inhibitor (TRKi).
Journal ArticleDOI
RWD43 Comparison of All-Cause Healthcare Resource Utilization Rates between Patients with Type 2 Diabetes Who Use a Digital Diabetes Solution Versus Non-Users: A 12-Month Retrospective Cohort Study
D. John Malone,Praveen K. Potukuchi,Nita K. Thingalaya,K Lee,Amy Kennedy,E. Han-Burgess,Diana L. Brixner +6 more
TL;DR: Dario Diabetes Solution (DDS) is a digital health application (app) for type 2 diabetes mellitus (T2DM) management, which combines a blood glucose (BG) meter and a mobile app, allowing patients to track BG levels in real-time as mentioned in this paper .
Journal ArticleDOI
Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study
Connor Willis,Hillevi Bauer,Trang H. Au,Jyothi Menon,Sudhir Unni,D. Tran,Zachary Rivers,Wallace Akerley,Matthew B. Schabath,Firas Benyamine Badin,Ashley Sekhon,Malini Patel,Bo Xia,B. Gustafson,John L. Villano,John M. Thomas,Solomon J. Lubinga,Michael A. Cantrell,Diana L. Brixner,David D. Stenehjem +19 more
TL;DR: TMB levels greater than or equal to 10 mut/Mb, when tested by Foundation Medicine or Caris at treatment initiation, were significantly associated with improved OS and PFS among patients treated with first-line immunotherapy-containing regimens.